MX2024010741A - Profarmacos de decanoato de abiraterona y uso en terapia. - Google Patents

Profarmacos de decanoato de abiraterona y uso en terapia.

Info

Publication number
MX2024010741A
MX2024010741A MX2024010741A MX2024010741A MX2024010741A MX 2024010741 A MX2024010741 A MX 2024010741A MX 2024010741 A MX2024010741 A MX 2024010741A MX 2024010741 A MX2024010741 A MX 2024010741A MX 2024010741 A MX2024010741 A MX 2024010741A
Authority
MX
Mexico
Prior art keywords
abiraterone
decanoate
prodrugs
therapy
sex hormone
Prior art date
Application number
MX2024010741A
Other languages
English (en)
Spanish (es)
Inventor
Matthew J Sharp
Jr William R Moore
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of MX2024010741A publication Critical patent/MX2024010741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024010741A 2022-03-01 2023-02-15 Profarmacos de decanoato de abiraterona y uso en terapia. MX2024010741A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315240P 2022-03-01 2022-03-01
US202263425839P 2022-11-16 2022-11-16
PCT/US2023/013116 WO2023167783A1 (en) 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy

Publications (1)

Publication Number Publication Date
MX2024010741A true MX2024010741A (es) 2024-09-10

Family

ID=85724851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010741A MX2024010741A (es) 2022-03-01 2023-02-15 Profarmacos de decanoato de abiraterona y uso en terapia.

Country Status (12)

Country Link
US (1) US20250186463A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486353A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508944A (cg-RX-API-DMAC7.html)
KR (1) KR20240167653A (cg-RX-API-DMAC7.html)
CN (1) CN119136813A (cg-RX-API-DMAC7.html)
AU (1) AU2023229152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013267A2 (cg-RX-API-DMAC7.html)
IL (1) IL315174A (cg-RX-API-DMAC7.html)
MX (1) MX2024010741A (cg-RX-API-DMAC7.html)
WO (1) WO2023167783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Also Published As

Publication number Publication date
CA3243913A1 (en) 2023-09-07
IL315174A (en) 2024-10-01
CO2024013267A2 (es) 2024-10-10
WO2023167783A1 (en) 2023-09-07
CL2024002613A1 (es) 2025-02-07
US20250186463A1 (en) 2025-06-12
CN119136813A (zh) 2024-12-13
EP4486353A1 (en) 2025-01-08
KR20240167653A (ko) 2024-11-27
AU2023229152A1 (en) 2024-09-05
JP2025508944A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
EP4286006A3 (en) Abiraterone prodrugs
MX2023002478A (es) Profarmacos de abiraterona.
PH12022551486A1 (en) Compounds and methods for the targeted degradation of androgen receptor
MX2021007927A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
MY209010A (en) Combination therapy for prostate cancer
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
WO2022031642A3 (en) Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
PH12020551715A1 (en) Methods of treating cancer
MX2024007260A (es) Uso de terapia de combinacion para tratar el cancer.
MX2022000853A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
PH12020550151A1 (en) Methods of treating prostate cancer
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
MX2023012768A (es) Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores.
MX2015006931A (es) Terapia combinada para tratar cánceres her2-positivos.
CO2024013267A2 (es) Profármacos de decanoato de abiraterona y uso en terapia
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
RU2011108558A (ru) Фармацевтические применения ланоста-8, 24-диен-3-олов
MX2024012369A (es) Terapia combinada para el tratamiento del cancer
BRPI0806257A2 (pt) método de tratamento, e, uso de uma composição imunoterapêutica
MX2023005314A (es) Composiciones de nanoparticulas para tratamiento de cancer.
MX2023003404A (es) Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.
ZA202304528B (en) A method of characterizing and evaluating a targeted drug delivery for malignant tumours